Flavonoids from Extract Butanol of Twigs Erythrina crista-galli Against the Breast Cancer Cell Line Within In Silico Method
DOI:
https://doi.org/10.48048/tis.2023.5350Keywords:
Flavonoid, Butanol extract, Erythrina crista-galli, In silico, Breast cancerAbstract
Breast cancer is one of the most serious health problems in the world. The common treatments for breast cancer have side effects and resistance, so the search for cancer drugs from natural products that are more effective is still a concern for researchers. Flavonoids from Erythrina crista-galli, which is one of the natural products, have the potential as anticancer drugs based on their phytoestrogen activity that has been reported. The aim of this research is to isolate flavonoids from extract butanol of E. crista-galli with column chromatography and determine their anticancer activity by the in silico molecular docking method. Two flavonoid compounds with the names 6,8-diprenylgenistein from the isoflavone group and phaseolin from the pterocarpan group were isolated. Molecular docking analysis showed that the highest binding affinity values for compounds 1 and 2 were to CDK-2 protein with values of −10.14 and −8.8 kcal/mol, respectively. However, it is also possible to suggest inhibition through ER protein, especially in compound 1, with a value of −10.66 kcal/mol. Therefore, inhibition of the target CDK-2 enzyme is the most promising for the development of new drugs.
HIGHLIGHTS
- Flavonoids have been isolated from butanol extract
- 6,8-diprenylgenistein and phaseolin were first reported from the species Erythrina crista-galli
- 6,8-diprenylgenistein has the potential as a new drug candidate with the highest stability based on its ΔG value by targeting the CDK-2 protein within in silico method
GRAPHICAL ABSTRACT
Downloads
Metrics
References
Word Health Organization, Available at: https://www.who.int/news-room/factsheets/detail/cancer, accessed September 2020.
National Cancer Institute, Available at: https://www.cancer.gov/about-cancer/treatment/types, accessed September 2020.
A Pearce, M Haas, R Viney, SA Pearson, P Haywood, C Brown and R Ward. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLos One 2017; 12, e0184360.
S Crawford. Is is time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front. Pharmacol. 2013; 4, 68.
S Mitra and R Dash. Natural products for the management and prevention of breast cancer. Evid. Base. Compl. Alternative Med. 2018; 2018, 8324696.
AN Panche, D Diwan and SR Chandra. Flavonoids: An overview. J. Nutr. Sci. 2016; 5, e47.
NM Fahmy, E Al-Sayed, M El-Shazly and AN Singab. Comprehensive review on flavonoids biological activities of Erythrina plant species. Ind. Crop. Prod. 2018; 123, 500-38.
PH Nguyen, G Sharma, TT Dao, MN Uddin, KW Kang, DT Ndinteh, JT Mbafor and WK Oh. New prenylated isoflavonoids as protein tyrosine phosphatase 1B (PTP1B) inhibitors from Erythrina addisoniae. Bioorg. Med. Chem. 2012; 20, 6459-64.
RF Tchokouaha, X Alexi, E Chosson, T Besson, AL Skaltsounis, E Seguin, MN Alexis and J Wandji. Erymildbraedin A and B, two novel cytotoxic dimethylpyrano-isoflavones from the stem bark of Erythrina mildbraedii: Evaluation of their activity toward endocrine cancer cells. J. Enzym. Inhib. Med. Chem. 2010; 25, 228-33.
P Innok, T Rukachaisirikul, S Phongpaichit and A Suksamrarn. Fuscacarpans A - C, new pterocarpans from the stems of Erythrina fusca. Fitoterapia 2010; 81, 518-23.
SE Sajjadi, M Ghanadian, M Haghighi and L Mouhebat. Cytotoxic effect of cousinia verbascifolia bunge against OVCAR-3 and HT-29 cancer cells. J. Herbmed Pharmacol. 2015; 4, 15-9.
NS Ashmawy, ML Ashour, M Wink, M El-Shazly, FR Chang, N Swilam, AB Abdel-Naim and N Ayoub. Polyphenols from Erythrina crista-galli: Structures, molecular docking and phytoestrogenic activity. Molecules 2016; 21, 726.
W Cui, A Aouidate, S Wang, Q Yu, Y Li and S Yuan. Discovering anti-cancer drugs via computational methods. Front. Pharmacol. 2020; 11, 733.
S Tabassum, M Zaki, M Afzal and A Farukh. Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase Ia: In vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines. Eur. J. Med. Chem. 2014; 74, 509-23.
XY Meng, HX Zhang, M Mezei and M Cui. Molecular docking: A powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 2011; 7, 146-57.
MH Kang and CP Reynolds. Bcl-2 Inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Canc. Res. 2015; 5, 515-25.
W Cheng, Z Yang, S Wang, Y Li, H Wei, X Tian and Q Kan. Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures. Eur. J. Med. Chem. 2019; 164, 615-39.
A Uifălean, S Schneider, C Ionescu, M Lalk and CA Iuga. Soy isoflavones and breast cancer cell lines: Molecular mechanisms and future perspectives. Molecules 2015; 21, E13.
CM Schlotter, U Vogt, H Allgayer and B Brandt. Molecular targeted therapies for breast cancer treatment. Breast Canc. Res. 2008; 10, 211.
AK Koutras, G Fountzilas, KT Kalogeras, I Starakis, G Iconomou and HP Kalofonos. The upgraded role of HER3 and HER4 receptors in breast cancer. Crit. Rev. Oncol. Hematol. 2010; 74, 73-8.
S Movérare-Skrtic, AE Börjesson, HH Farman, K Sjögren, SH Windahl, MK Lagerquist, A Andersson, A Stubelius, H Carlsten, JÅ Gustafsson and C Ohlsson. The estrogen receptor antagonist ICI 182,780 can act both as an agonist and an inverse agonist when estrogen receptor α AF-2 is modified. Proc. Natl. Acad. Sci. Unit. States Am. 2014; 111, 1180-5.
K Markham. Cara mengidentifikasi flavonoid. Institut Teknologi Bandung, Bandung, Indonesia, 1998.
K Ashok, RP Sharma, G Thyagarajan, W Herz and SV Govindan. New prenylated isoflavones and a prenylated dihydroflavonol from illettia pachycarpa. Phytochemistry 1979; 19, 929-34.
Y Shirataki, A Manaka, I Yokoe and M Komatsu. Two Prenylflavanones from euchresta japonica. Phytochemistry 1982; 21, 2959-63.
SL Prasojo, FA Hartanto, N Yuniarti, Z Ikawati and EP Istyastono. Docking of 1-phenylsulfonamide-3-trifluoromethyl-5-parabromophenyl-pyrazole to cyclooxygenase-2 using plants. Indonesian J. Chem. 2010; 10, 348-51.
N Anggreini, RD Saputri, TS Tjahjandrie and M Tanjung. Aktivitas Antikanker Senyawa Pterokarpan Dari Erythrina fusca L. Pharm. Med. J. 2018; 1, 1-8.
D Chen, N Oezguen, P Urvil, C Ferguson, SM Dann and TC Savidge. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci. Adv. 2016; 2, e1501240.
IA Evangelina, Y Herdiyati, A Laviana, R Rikmasari and C Zubaedah. Bio-mechanism inhibitory prediction of β-sitosterol from kemangi (Ocimum basilicum L.) as an inhibitor of MurA enzyme of oral bacteria: In vitro and in silico study. Adv. Appl. Bioinformatics Chem. 2021; 14, 103-15.
K Dahlman-Wright, V Cavailles, SA Fuqua, VC Jordan, JA Katzenellenbogen, KS Korach, A Maggi, M Muramatsu, MG Parker and JÅ Gustafsson. International union of pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 2006; 58, 773-81.
DM Tanenbaum, Y Wang, SP Williams and PB Sigler. Crystallographic comparison of the estrogen and progesterone receptor’s ligand binding domains. Proc. Natl. Acad. Sci. Unit. States Am. 1998; 95, 5998-6003.
K Bukowski, M Kciuk and R Kontek. Mechanisms of multidrug resistance in cancer chemotherapy. Int. J. Mol. Sci. 2020; 21, 3233.
MP Kline, SV Rajkumar, MM Timm, TK Kimlinger, JL Haug, JA Lust, JA Lust, PR Greipp and S Kumar. ABT-737, an inhibitor of Bcl-2 family proteins, is A potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007; 21, 1549-60.
JB Murray, J Davidson, I Chen, B Davis, P Dokurno, CJ Graham, R Harris, A Jordan, N Matassova, C Pedder, S Ray, SD Roughley, J Smith, C Walmsley, Y Wang, N Whitehead, DS Williamson, P Casara, TL Diguarher, J Hickman, J Stark, A Kotschy, O Geneste and RE Hubbard. Establishing drug discovery and identification of hit series for the anti-apoptotic proteins, Bcl-2 and Mcl-1. ACS Omega 2019; 4, 8892-906.
A Echalier, JA Endicot and ME Noble. Recent developments in cyclin-dependent kinase biochemical and structural studies. Acta Biochim. Biophys. Sin. 2010; 1804, 511-9.
M Reck, L Horn, S Novello, F Barseli, I Albert, E Juhasz, D Kowalski, G Robinet, J Cadranel, P Bidoli, J Chung, A Fritsch, U Drews, A Wagner and R Govindan. Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J. Thorac. Oncol. 2019; 14, 701-11.
ST Davis, BG Benson, HN Bramson, DE Chapman, SH Dickerson, KM Dold, DJ Eberwein, M Edelstein, SV Frye, RT Gampe Jr, RJ Griffin, PA Harris, AM Hassell, WD Holmes, RN Hunter, VB Knick, K Lackey, B Lovejoy, MJ Luzzio, D Murray, P Parker, W J Rocque, L Shewchuk, JM Veal, DH Walker and LF Kuyper. Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 2001; 291, 134-7.
T Al-Warhi, MF Abo-Ashour, H Almahli, OJ Alotaibi, MM Al-Sanea, GH Al-Ansary, HY Ahmed, MM Elaasser, WM Eldehna and HA Abdel-Aziz. Novel [(N-alkyl-3-indolylmethylene)hydrazono]oxindoles arrest cell cycle and induce cell apoptosis by inhibiting CDK2 and Bcl-2: synthesis, biological evaluation and in silico studies. J. Enzym. Inhib. Med. Chem. 2020; 35, 1300-9.
Y Kawakita, M Seto, T Ohashi, T Tamura, T Yusa, H Miki, H Iwata, H Kamiguchi, T Tanaka, S Sogabe, Y Ohta and T Ishikawa. Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors. Bioorg. Med. Chem. 2013; 21, 2250-61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Walailak University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
